{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:10:48Z","timestamp":1794838248008,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster","id":[{"id":"https:\/\/ror.org\/01856cw59","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive disease in which cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival. However, recurrence rates remain high, highlighting the need for reliable prognostic factors to guide patient selection. This systematic review and meta-analysis aimed to evaluate prognostic factors in patients with DMPM undergoing CRS and HIPEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      A systematic literature search of PubMed, MEDLINE, Cochrane Library, Embase, Scopus, and Web of Science was performed up to July 2024. Studies reporting prognostic factors associated with overall and\/or progression-free survival were included. Data were pooled using random effects models. Heterogeneity was assessed using the\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistic and Cochran\u2019s Q test. Evaluation of publication bias and sensitivity analyses were conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of eleven\u00a0studies comprising 891 patients were included. Incomplete cytoreduction, elevated peritoneal cancer index, grade 3\u20135 postoperative morbidity, prior chemotherapy exposure, World Health Organization performance status\u2009\u2265\u20091, biphasic or sarcomatoid histology, and elevated Ki-67 proliferation index were consistently associated with poorer survival outcomes. Evidence for additional prognostic factors was limited. No prognostic molecular biomarkers could be identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Established clinical\u2013pathological, histological, and immunohistochemical parameters remain the most relevant prognostic factors in patients with DMPM undergoing CRS and HIPEC. These findings facilitate more refined patient selection and support the ongoing standardization of HIPEC protocols for this uncommon and aggressive malignancy. However, the current evidence base is limited and should be interpreted with caution. Future research should prioritize the integration of molecular and genetic biomarkers to enhance prognostic stratification and support personalized treatment approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20426-5","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:52:25Z","timestamp":1787662345000},"page":"11247-11266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Factors in Patients with Peritoneal Mesothelioma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9248-2294","authenticated-orcid":false,"given":"Jan Philipp","family":"Ramspott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kolmhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"B\u00fcdeyri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weitzendorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Regenbogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Schabl-Cayron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schredl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D.","family":"Bungert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Bekric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Presl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Neureiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarkan","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"20426_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology, Mesothelioma: Peritoneal, Version 2.2026 - October 3, (2025). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/meso_peritoneal.pdf. Accessed 04 Jan 2026."},{"issue":"5","key":"20426_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/jso.27947","volume":"131","author":"S Kusamura","year":"2025","unstructured":"Kusamura S, Cinquini M, Morris D, et al. Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of diffuse malignant peritoneal mesothelioma: a GRADE approach for evidence evaluation and recommendation. J Surg Oncol. 2025;131(5):810\u20135. https:\/\/doi.org\/10.1002\/jso.27947.","journal-title":"J Surg Oncol."},{"issue":"6","key":"20426_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18(6):985\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdl345.","journal-title":"Ann Oncol."},{"issue":"1","key":"20426_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/jwh.2019.7752","volume":"29","author":"SJ Henley","year":"2020","unstructured":"Henley SJ, Peipins LA, Rim SH, et al. Geographic co-occurrence of mesothelioma and ovarian cancer incidence. J Womens Health (Larchmt). 2020;29(1):111\u20138. https:\/\/doi.org\/10.1089\/jwh.2019.7752.","journal-title":"J Womens Health (Larchmt)."},{"issue":"5","key":"20426_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402\u201329. https:\/\/doi.org\/10.3322\/caac.21572.","journal-title":"CA Cancer J Clin."},{"issue":"4","key":"20426_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3390\/cancers14040942","volume":"14","author":"A Ullah","year":"2022","unstructured":"Ullah A, Waheed A, Khan J, Mishra A, Tareen B, Nama N, Karki NR, Panezai MS, Zarate LV, White J, Cason FD. Incidence, survival analysis and future perspective of primary peritoneal mesothelioma (PPM): a population-based study from SEER database. Cancers. 2022;14(4):942. https:\/\/doi.org\/10.3390\/cancers14040942.","journal-title":"Cancers."},{"key":"20426_CR7","doi-asserted-by":"publisher","first-page":"e2100422","DOI":"10.1200\/PO.21.00422","volume":"6","author":"I Dagogo-Jack","year":"2022","unstructured":"Dagogo-Jack I, Madison RW, Lennerz JK, Chen KT, Hopkins JF, Schrock AB, Ritterhouse LL, Lester A, Wharton KA Jr, Mino-Kenudson M, Danziger N. Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape. JCO Precis Oncol. 2022;6:e2100422.","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"20426_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","volume":"17","author":"AC Borczuk","year":"2016","unstructured":"Borczuk AC, Pei J, Taub RN, et al. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther. 2016;17(3):328\u201335. https:\/\/doi.org\/10.1080\/15384047.2016.1145850.","journal-title":"Cancer Biol Ther."},{"issue":"1","key":"20426_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-015-0485-1","volume":"13","author":"H Alakus","year":"2015","unstructured":"Alakus H, Yost SE, Woo B, French R, Lin GY, Jepsen K, Frazer KA, Lowy AM, Harismendy O. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Translat Med. 2015;13(1):122. https:\/\/doi.org\/10.1186\/s12967-015-0485-1.","journal-title":"J Translat Med."},{"issue":"2","key":"20426_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","volume":"4","author":"YP Hung","year":"2018","unstructured":"Hung YP, Dong F, Watkins JC, et al. Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol. 2018;4(2):235\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2918.","journal-title":"JAMA Oncol."},{"issue":"4","key":"20426_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","volume":"12","author":"N Leblay","year":"2017","unstructured":"Leblay N, Lepr\u00eatre F, Le Stang N, et al. BAP1 is altered by copy number loss, mutation, and\/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol. 2017;12(4):724\u201333. https:\/\/doi.org\/10.1016\/j.jtho.2016.12.019.","journal-title":"J Thorac Oncol."},{"key":"20426_CR12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1200\/po.21.00184","volume":"5","author":"V Gerthofer","year":"2021","unstructured":"Gerthofer V, Scheiter A, L\u00fcke F, Keil F, Utpatel K, P\u00f6hmerer LM, Seitz J, Niessen C, Ignatov A, Dietmaier W, Calvisi DF. STRN-ALK fusion in a case of malignant peritoneal mesothelioma: mixed response to crizotinib, mode of resistance, and brigatinib sequential therapy. JCO Precis Oncol. 2021;5:1507\u201313. https:\/\/doi.org\/10.1200\/po.21.00184.","journal-title":"JCO Precis Oncol."},{"issue":"1","key":"20426_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/00031348251350994","volume":"92","author":"H Bhatt","year":"2026","unstructured":"Bhatt H, Vakil DP, Quintero L, et al. Characteristics of long-term survivors with peritoneal mesothelioma - Insights from the National Cancer Database. Am Surg. 2026;92(1):53\u201361. https:\/\/doi.org\/10.1177\/00031348251350994.","journal-title":"Am Surg."},{"issue":"5","key":"20426_CR14","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686\u201393. https:\/\/doi.org\/10.1245\/s10434-014-3978-x.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"20426_CR15","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1245\/s10434-023-13973-8","volume":"30","author":"V Kepenekian","year":"2023","unstructured":"Kepenekian V, Sgarbura O, Marchal F, et al. 2022 PSOGI consensus on HIPEC regimens for peritoneal malignancies: diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2023;30(12):7803\u201313. https:\/\/doi.org\/10.1245\/s10434-023-13973-8.","journal-title":"Ann Surg Oncol."},{"key":"20426_CR16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17358-x","author":"LM Brown","year":"2025","unstructured":"Brown LM, Wilkins SG, Bansal VV, et al. Consensus guideline for the management of peritoneal mesothelioma. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17358-x.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20426_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","volume":"47","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36\u201359. https:\/\/doi.org\/10.1016\/j.ejso.2020.02.011.","journal-title":"Eur J Surg Oncol."},{"key":"20426_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ."},{"key":"20426_CR19","doi-asserted-by":"publisher","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","DOI":"10.1136\/bmj.j4008"},{"issue":"7524","key":"20426_CR20","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/bmj.38636.593461.68","volume":"331","author":"T Greenhalgh","year":"2005","unstructured":"Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ. 2005;331(7524):1064\u20135. https:\/\/doi.org\/10.1136\/bmj.38636.593461.68.","journal-title":"BMJ."},{"issue":"3","key":"20426_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Softw."},{"key":"20426_CR22","unstructured":"R Core Team (2025). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: https:\/\/www.R-project.org\/. Accessed: 11 May 2025."},{"issue":"5","key":"20426_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/cancers18050795","volume":"18","author":"JP Ramspott","year":"2026","unstructured":"Ramspott JP, Kolmhofer A, Schabl-Cayron L, Schredl P, Emmanuel K, Bekric D, Presl J, Pascher A, Neureiter D, J\u00e4ger T. The Role of Prognostic Clinical-Pathological,(Immuno-) Histological, and Molecular Parameters in Pseudomyxoma Peritonei Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis. Cancers. 2026;18(5):795. https:\/\/doi.org\/10.3390\/cancers18050795.","journal-title":"Cancers."},{"issue":"11","key":"20426_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med."},{"issue":"7109","key":"20426_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ."},{"key":"20426_CR26","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed: 08 Dec 2025."},{"issue":"7454","key":"20426_CR27","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. https:\/\/doi.org\/10.1136\/bmj.328.7454.1490.","journal-title":"BMJ."},{"issue":"8","key":"20426_CR28","doi-asserted-by":"publisher","first-page":"e007070","DOI":"10.1136\/jitc-2023-007070","volume":"11","author":"MV Dietz","year":"2023","unstructured":"Dietz MV, Quintelier KL, van Kooten JP, de Boer NL, Vink M, Brandt-Kerkhof AR, Verhoef C, Saeys Y, Aerts JG, Willemsen M, Van Gassen S. Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial. J Immunother Cancer. 2023;11(8):e007070.","journal-title":"J Immunother Cancer."},{"issue":"277","key":"20426_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jss.2022.04.005","volume":"1","author":"VP Gazivoda","year":"2022","unstructured":"Gazivoda VP, Kangas-Dick AW, Greenbaum AA, Roshal J, Chen C, Moore DF, Langan RC, Kennedy TJ, Minerowicz C, Alexander HR. Expression of PD-L1 in patients with malignant peritoneal mesothelioma: a pilot study. J Surg Res. 2022;1(277):131\u20137. https:\/\/doi.org\/10.1016\/j.jss.2022.04.005.","journal-title":"J Surg Res."},{"issue":"1","key":"20426_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s40064-016-1998-7","volume":"5","author":"X Cheng","year":"2016","unstructured":"Cheng X, Gou HF, Liu JY, Luo DY, Qiu M. Clinical significance of serum CA125 in diffuse malignant mesothelioma. SpringerPlus. 2016;5(1):368. https:\/\/doi.org\/10.1186\/s40064-016-1998-7.","journal-title":"SpringerPlus."},{"issue":"11","key":"20426_CR31","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ejso.2010.08.130","volume":"36","author":"D Baratti","year":"2010","unstructured":"Baratti D, Vaira M, Kusamura S, et al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2010;36(11):1047\u201353. https:\/\/doi.org\/10.1016\/j.ejso.2010.08.130.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"20426_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12253-009-9210-9","volume":"16","author":"TC Chua","year":"2010","unstructured":"Chua TC, Yao P, Akther J, et al. Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy. Pathol Oncol Res. 2010;16(2):217\u201322. https:\/\/doi.org\/10.1007\/s12253-009-9210-9.","journal-title":"Pathol Oncol Res."},{"issue":"1","key":"20426_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1245\/s10434-008-0206-6","volume":"16","author":"JM Foster","year":"2009","unstructured":"Foster JM, Gatalica Z, Lilleberg S, et al. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol. 2009;16(1):152\u20138. https:\/\/doi.org\/10.1245\/s10434-008-0206-6.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20426_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jso.20266","volume":"91","author":"KE Bani-Hani","year":"2005","unstructured":"Bani-Hani KE, Gharaibeh KA. Malignant peritoneal mesothelioma. J Surg Oncol. 2005;91(1):17\u201325. https:\/\/doi.org\/10.1002\/jso.20266.","journal-title":"J Surg Oncol."},{"issue":"10","key":"20426_CR35","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.ejso.2017.05.009","volume":"43","author":"S Valmary-Degano","year":"2017","unstructured":"Valmary-Degano S, Colpart P, Villeneuve L, et al. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study. Eur J Surg Oncol. 2017;43(10):1915\u201323. https:\/\/doi.org\/10.1016\/j.ejso.2017.05.009.","journal-title":"Eur J Surg Oncol."},{"issue":"8","key":"20426_CR36","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1245\/s10434-017-5834-2","volume":"24","author":"YC Li","year":"2017","unstructured":"Li YC, Khashab T, Terhune J, et al. Preoperative thrombocytosis predicts shortened survival in patients with malignant peritoneal mesothelioma undergoing operative cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2017;24(8):2259\u201365. https:\/\/doi.org\/10.1245\/s10434-017-5834-2.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"20426_CR37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1245\/s10434-006-9192-8","volume":"14","author":"D Baratti","year":"2007","unstructured":"Baratti D, Kusamura S, Martinetti A, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14(2):500\u20138. https:\/\/doi.org\/10.1245\/s10434-006-9192-8.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"20426_CR38","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1245\/s10434-015-4498-z","volume":"22","author":"M Deraco","year":"2015","unstructured":"Deraco M, Cabras A, Baratti D, et al. Immunohistochemical evaluation of minichromosome maintenance protein 7 (MCM7), topoisomerase II\u03b1, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol. 2015;22(13):4344\u201351. https:\/\/doi.org\/10.1245\/s10434-015-4498-z.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20426_CR39","first-page":"312","volume":"3","author":"K Pillai","year":"2013","unstructured":"Pillai K, Pourgholami MH, Chua TC, et al. Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma? Am J Cancer Res. 2013;3(3):312\u201322.","journal-title":"Am J Cancer Res."},{"issue":"12","key":"20426_CR40","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1245\/s10434-013-3077-4","volume":"20","author":"J Hommell-Fontaine","year":"2013","unstructured":"Hommell-Fontaine J, Isaac S, Passot G, et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A prelim study Ann Surg Oncol. 2013;20(12):3892\u20138. https:\/\/doi.org\/10.1245\/s10434-013-3077-4.","journal-title":"A prelim study. Ann Surg Oncol."},{"issue":"4","key":"20426_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jso.21057","volume":"98","author":"R Younan","year":"2008","unstructured":"Younan R, Kusamura S, Baratti D, et al. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):253\u20137. https:\/\/doi.org\/10.1002\/jso.21057.","journal-title":"J Surg Oncol."},{"issue":"11","key":"20426_CR42","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1245\/s10434-018-6630-3","volume":"25","author":"E Nizri","year":"2018","unstructured":"Nizri E, Kusamura S, Fallabrino G, et al. Dose-dependent effect of red blood cells transfusion on perioperative and long-term outcomes in peritoneal surface malignancies treated with cytoreduction and HIPEC. Ann Surg Oncol. 2018;25(11):3264\u201370. https:\/\/doi.org\/10.1245\/s10434-018-6630-3.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"20426_CR43","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1245\/s10434-015-4962-9","volume":"23","author":"S Kusamura","year":"2016","unstructured":"Kusamura S, Torres Mesa PA, Cabras A, et al. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23(5):1468\u201373. https:\/\/doi.org\/10.1245\/s10434-015-4962-9.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"20426_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1245\/aso.2006.03.045","volume":"13","author":"M Deraco","year":"2006","unstructured":"Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229\u201337. https:\/\/doi.org\/10.1245\/aso.2006.03.045.","journal-title":"Ann Surg Oncol."},{"issue":"15","key":"20426_CR45","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49(15):3140\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2013.05.027.","journal-title":"Eur J Cancer."},{"issue":"6","key":"20426_CR46","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ejso.2018.02.010","volume":"44","author":"F Bruno","year":"2018","unstructured":"Bruno F, Baratti D, Martinetti A, et al. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: a preliminary study. Eur J Surg Oncol. 2018;44(6):792\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2018.02.010.","journal-title":"Eur J Surg Oncol."},{"issue":"13","key":"20426_CR47","doi-asserted-by":"publisher","first-page":"9731","DOI":"10.1245\/s10434-025-18196-7","volume":"32","author":"J P\u00e9ron","year":"2025","unstructured":"P\u00e9ron J, Essadi I, Rousset P, et al. Assessing the annual risk of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma patients. Ann Surg Oncol. 2025;32(13):9731\u201340. https:\/\/doi.org\/10.1245\/s10434-025-18196-7.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20426_CR48","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1245\/s10434-017-6293-5","volume":"25","author":"KI Votanopoulos","year":"2018","unstructured":"Votanopoulos KI, Sugarbaker P, Deraco M, et al. Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol. 2018;25(3):667\u201373. https:\/\/doi.org\/10.1245\/s10434-017-6293-5.","journal-title":"Ann Surg Oncol."},{"key":"20426_CR49","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000003107","author":"X Wei","year":"2025","unstructured":"Wei X, Liao P, Chen X, et al. Risk factors affecting prognosis in pseudomyxoma peritonei patients after hyperthermic intraperitoneal chemotherapy and cytoreductive surgery: a systematic review and meta-analysis. Int J Surg. 2025. https:\/\/doi.org\/10.1097\/js9.0000000000003107.","journal-title":"Int J Surg."},{"issue":"2","key":"20426_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/SLA.0b013e31825704e3","volume":"256","author":"D Baratti","year":"2012","unstructured":"Baratti D, Kusamura S, Mingrone E, et al. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2012;256(2):334\u201341. https:\/\/doi.org\/10.1097\/SLA.0b013e31825704e3.","journal-title":"Ann Surg."},{"issue":"6","key":"20426_CR51","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/wjs.12601","volume":"49","author":"A Ashraf Ganjouei","year":"2025","unstructured":"Ashraf Ganjouei A, Wang J, Yi C, et al. Predicting severe postoperative complications after CRS-HIPEC: an externally validated machine-learning tool. World J Surg. 2025;49(6):1546\u201354. https:\/\/doi.org\/10.1002\/wjs.12601.","journal-title":"World J Surg."},{"issue":"45","key":"20426_CR52","doi-asserted-by":"publisher","first-page":"101884","DOI":"10.1016\/j.suronc.2022.101884","volume":"1","author":"C Riediger","year":"2022","unstructured":"Riediger C, Schuster T, Bork U, Schweipert J, Sigg M, Weiss J, Weitz J. Do certain surgical steps increase postoperative morbidity after cytoreductive surgery and HIPEC-a retrospective analysis. Surg Oncol. 2022;1(45):101884.","journal-title":"Surg Oncol."},{"issue":"1","key":"20426_CR53","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1245\/s10434-018-6992-6","volume":"26","author":"P Piso","year":"2019","unstructured":"Piso P, Nedelcut SD, Rau B, et al. Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol. 2019;26(1):148\u201354. https:\/\/doi.org\/10.1245\/s10434-018-6992-6.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20426_CR54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00384-024-04741-5","volume":"39","author":"D Chen","year":"2024","unstructured":"Chen D, Ma Y, Li J, et al. Risk factors for postoperative complications in patients undergoing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: a meta-analysis and systematic review. Int J Colorectal Dis. 2024;39(1):167. https:\/\/doi.org\/10.1007\/s00384-024-04741-5.","journal-title":"Int J Colorectal Dis."},{"issue":"17","key":"20426_CR55","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.3390\/jcm13175182","volume":"13","author":"ME Alberto Vilchez","year":"2024","unstructured":"Alberto Vilchez ME, Halskov S, Winter A, Pratschke J, Rau B, G\u00fcl S. Morbidity and mortality after cytoreductive surgery and HIPEC in a national reference center: a six-year experience under independent evaluation. J Clin Med. 2024;13(17):5182. https:\/\/doi.org\/10.3390\/jcm13175182.","journal-title":"J Clin Med."},{"issue":"4","key":"20426_CR56","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/ans.18833","volume":"94","author":"JH Lim","year":"2024","unstructured":"Lim JH, Qin RX, Ly J, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in New Zealand: peri-operative outcomes and service development over a decade. ANZ J Surg. 2024;94(4):614\u201320. https:\/\/doi.org\/10.1111\/ans.18833.","journal-title":"ANZ J Surg."},{"issue":"12","key":"20426_CR57","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/s1470-2045(24)00531-x","volume":"25","author":"JM Classe","year":"2024","unstructured":"Classe JM, Meeus P, Hudry D, et al. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024;25(12):1551\u201362. https:\/\/doi.org\/10.1016\/s1470-2045(24)00531-x.","journal-title":"Lancet Oncol."},{"issue":"4","key":"20426_CR58","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ejso.2019.10.032","volume":"46","author":"SP Somashekhar","year":"2020","unstructured":"Somashekhar SP, Yethadka R, Kumar R, Ashwin KR, Zaveri S, Rauthan A. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. European J Surg Oncol. 2020;46(4):577\u201381. https:\/\/doi.org\/10.1016\/j.ejso.2019.10.032.","journal-title":"European J Surg Oncol."},{"issue":"2","key":"20426_CR59","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/s1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"4","key":"20426_CR60","doi-asserted-by":"publisher","first-page":"111492","DOI":"10.1016\/j.ejso.2026.111492","volume":"52","author":"B Noiret","year":"2026","unstructured":"Noiret B, Lenne X, Piessen G, et al. Ten-year of French multicentric experience in the management of peritoneal mesothelioma with 924 patients. Eur J Surg Oncol. 2026;52(4):111492. https:\/\/doi.org\/10.1016\/j.ejso.2026.111492.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"20426_CR61","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1245\/s10434-024-16485-1","volume":"32","author":"XL Liang","year":"2025","unstructured":"Liang XL, Su YD, Li XB, et al. Prognostic factors of long-term survival and conditional survival analysis in MPM patients treated with CRS+HIPEC: a retrospective study of two centers. Ann Surg Oncol. 2025;32(4):2912\u201322. https:\/\/doi.org\/10.1245\/s10434-024-16485-1.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20426_CR62","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/02656736.2022.2066728","volume":"39","author":"YD Su","year":"2022","unstructured":"Su YD, Yang ZR, Li XB, et al. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China. Int J Hyperthermia. 2022;39(1):706\u201312. https:\/\/doi.org\/10.1080\/02656736.2022.2066728.","journal-title":"Int J Hyperthermia."},{"issue":"36","key":"20426_CR63","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/jco.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u201342. https:\/\/doi.org\/10.1200\/jco.2009.23.9640.","journal-title":"J Clin Oncol."},{"issue":"2","key":"20426_CR64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"issue":"1","key":"20426_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0b013e318296c732","volume":"258","author":"K Slankamenac","year":"2013","unstructured":"Slankamenac K, Graf R, Barkun J, et al. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258(1):1\u20137. https:\/\/doi.org\/10.1097\/SLA.0b013e318296c732.","journal-title":"Ann Surg."},{"issue":"65","key":"20426_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"1","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D, Quenet F, Ferron G, Pezet D, Guilloit JM, Meeus P. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. European J Cancer. 2016;1(65):69\u201379. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.002.","journal-title":"European J Cancer."},{"issue":"1","key":"20426_CR67","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1245\/s10434-023-13640-y","volume":"31","author":"A Chatterjee","year":"2024","unstructured":"Chatterjee A, Kusamura S, Baratti D, et al. Impact of perioperative systemic chemotherapy on survival for patients who have diffuse malignant peritoneal mesothelioma treated with CRS-HIPEC. Ann Surg Oncol. 2024;31(1):556\u201366. https:\/\/doi.org\/10.1245\/s10434-023-13640-y.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"20426_CR68","doi-asserted-by":"publisher","first-page":"e0275187","DOI":"10.1371\/journal.pone.0275187","volume":"17","author":"X Wang","year":"2022","unstructured":"Wang X, Katz S, Miura J, et al. A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma. PLoS One. 2022;17(9):e0275187. https:\/\/doi.org\/10.1371\/journal.pone.0275187.","journal-title":"PLoS One."},{"issue":"4","key":"20426_CR69","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, et al. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(4):1093\u2013100. https:\/\/doi.org\/10.1245\/s10434-012-2845-x.","journal-title":"Ann Surg Oncol."},{"key":"20426_CR70","doi-asserted-by":"publisher","unstructured":"Mansfield AS, Goodrich A, Foster NR, et al. Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001). J Clin Oncol. 2023;41 (16_suppl):TPS8603. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS8603.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8603"},{"issue":"1","key":"20426_CR71","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12957-018-1350-5","volume":"16","author":"W Yin","year":"2018","unstructured":"Yin W, Zheng G, Yang K, et al. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma. World J Surg Oncol. 2018;16(1):44. https:\/\/doi.org\/10.1186\/s12957-018-1350-5.","journal-title":"World J Surg Oncol."},{"issue":"2","key":"20426_CR72","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11605-014-2664-4","volume":"19","author":"S Jin","year":"2015","unstructured":"Jin S, Cao S, Cao J, et al. Predictive factors analysis for malignant peritoneal mesothelioma. J Gastrointest Surg. 2015;19(2):319\u201326. https:\/\/doi.org\/10.1007\/s11605-014-2664-4.","journal-title":"J Gastrointest Surg."},{"issue":"8","key":"20426_CR73","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1245\/s10434-016-5172-9","volume":"23","author":"Y Huang","year":"2016","unstructured":"Huang Y, Alzahrani NA, Chua TC, et al. Impacts of preoperative serum albumin level on outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(8):2411\u20138. https:\/\/doi.org\/10.1245\/s10434-016-5172-9.","journal-title":"Ann Surg Oncol."},{"issue":"15","key":"20426_CR74","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591\u2013603. https:\/\/doi.org\/10.1056\/NEJMra050152.","journal-title":"N Engl J Med."},{"issue":"2","key":"20426_CR75","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jpen.1451","volume":"43","author":"PB Soeters","year":"2019","unstructured":"Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181\u201393. https:\/\/doi.org\/10.1002\/jpen.1451.","journal-title":"JPEN J Parenter Enteral Nutr."},{"issue":"2","key":"20426_CR76","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/annonc\/mdp307","volume":"21","author":"VP Manzini","year":"2010","unstructured":"Manzini VP, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21(2):348\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdp307.","journal-title":"Ann Oncol."},{"issue":"5","key":"20426_CR77","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/hep.1840080521","volume":"8","author":"BA Runyon","year":"1988","unstructured":"Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8(5):1104\u20139. https:\/\/doi.org\/10.1002\/hep.1840080521.","journal-title":"Hepatology."},{"issue":"2","key":"20426_CR78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.14670\/hh-18-033","volume":"34","author":"L Lacina","year":"2019","unstructured":"Lacina L, Br\u00e1bek J, Kr\u00e1l V, et al. Interleukin-6: a molecule with complex biological impact in cancer. Histol Histopathol. 2019;34(2):125\u201336. https:\/\/doi.org\/10.14670\/hh-18-033.","journal-title":"Histol Histopathol."},{"issue":"14","key":"20426_CR79","doi-asserted-by":"publisher","first-page":"1116430","DOI":"10.3389\/fimmu.2023.1116430","volume":"16","author":"E Digifico","year":"2023","unstructured":"Digifico E, Erreni M, Mannarino L, Marchini S, Ummarino A, Anfray C, Bertola L, Recordati C, Pistillo D, Roncalli M, Bossi P. Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma. Front Immunol. 2023;16(14):1116430. https:\/\/doi.org\/10.3389\/fimmu.2023.1116430.","journal-title":"Front Immunol."},{"issue":"13","key":"20426_CR80","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/onc.2009.478","volume":"29","author":"K Tajima","year":"2010","unstructured":"Tajima K, Ohashi R, Sekido Y, et al. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010;29(13):1941\u201351. https:\/\/doi.org\/10.1038\/onc.2009.478.","journal-title":"Oncogene."},{"issue":"3","key":"20426_CR81","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.bbrc.2009.03.042","volume":"382","author":"SV Ivanov","year":"2009","unstructured":"Ivanov SV, Ivanova AV, Goparaju CM, et al. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun. 2009;382(3):514\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2009.03.042.","journal-title":"Biochem Biophys Res Commun."},{"issue":"2","key":"20426_CR82","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41379-020-00688-4","volume":"34","author":"DB Chapel","year":"2021","unstructured":"Chapel DB, Schulte JJ, Absenger G, et al. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol. 2021;34(2):380\u201395. https:\/\/doi.org\/10.1038\/s41379-020-00688-4.","journal-title":"Mod Pathol."},{"issue":"1","key":"20426_CR83","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/his.15065","volume":"84","author":"JJ Schulte","year":"2024","unstructured":"Schulte JJ, Husain AN. Updates on grading mesothelioma. Histopathology. 2024;84(1):153\u201362. https:\/\/doi.org\/10.1111\/his.15065.","journal-title":"Histopathology."},{"issue":"2","key":"20426_CR84","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/modpathol.2011.146","volume":"25","author":"K Kadota","year":"2012","unstructured":"Kadota K, Suzuki K, Colovos C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol. 2012;25(2):260\u201371. https:\/\/doi.org\/10.1038\/modpathol.2011.146.","journal-title":"Mod Pathol."},{"issue":"4","key":"20426_CR85","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/modpathol.2017.170","volume":"31","author":"LE Rosen","year":"2018","unstructured":"Rosen LE, Karrison T, Ananthanarayanan V, et al. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018;31(4):598\u2013606. https:\/\/doi.org\/10.1038\/modpathol.2017.170.","journal-title":"Mod Pathol."},{"issue":"1","key":"20426_CR86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","volume":"15","author":"AG Nicholson","year":"2020","unstructured":"Nicholson AG, Sauter JL, Nowak AK, et al. EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol. 2020;15(1):29\u201349. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.2506.","journal-title":"J Thorac Oncol."},{"issue":"5","key":"20426_CR87","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/his.12807","volume":"68","author":"AM Krasinskas","year":"2016","unstructured":"Krasinskas AM, Borczuk AC, Hartman DJ, et al. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology. 2016;68(5):729\u201337. https:\/\/doi.org\/10.1111\/his.12807.","journal-title":"Histopathology."},{"issue":"9","key":"20426_CR88","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1158\/1078-0432.Ccr-04-1884","volume":"11","author":"AC Borczuk","year":"2005","unstructured":"Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11(9):3303\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-1884.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"20426_CR89","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/cancers17020252","volume":"17","author":"A D\u2019amati","year":"2025","unstructured":"D\u2019amati A, Serio G, Quaranta A, Vimercati L, De Giorgis M, Lorusso L, Errede M, Longo V, Marzullo A, Ribatti D, Annese T. Analysis of TERT mRNA levels and clinicopathological features in patients with peritoneal mesothelioma. Cancers. 2025;17(2):252. https:\/\/doi.org\/10.3390\/cancers17020252.","journal-title":"Cancers."},{"issue":"9","key":"20426_CR90","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/pas.0000000000000696","volume":"40","author":"K Valente","year":"2016","unstructured":"Valente K, Blackham AU, Levine E, et al. A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype. Am J Surg Pathol. 2016;40(9):1243\u20138. https:\/\/doi.org\/10.1097\/pas.0000000000000696.","journal-title":"Am J Surg Pathol."},{"issue":"6","key":"20426_CR91","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00428-017-2109-z","volume":"470","author":"C Habougit","year":"2017","unstructured":"Habougit C, Trombert-Paviot B, Karpathiou G, et al. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies. Virchows Arch. 2017;470(6):639\u201346. https:\/\/doi.org\/10.1007\/s00428-017-2109-z.","journal-title":"Virchows Arch."},{"issue":"4","key":"20426_CR92","first-page":"411","volume":"3","author":"K Pillai","year":"2013","unstructured":"Pillai K, Pourgholami MH, Chua TC, et al. Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res. 2013;3(4):411\u201323.","journal-title":"Am J Cancer Res."},{"issue":"7","key":"20426_CR93","doi-asserted-by":"publisher","first-page":"804","DOI":"10.5858\/arpa.2011-0219-OA","volume":"136","author":"SM Lagana","year":"2012","unstructured":"Lagana SM, Taub RN, Borczuk AC. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med. 2012;136(7):804\u20139. https:\/\/doi.org\/10.5858\/arpa.2011-0219-OA.","journal-title":"Arch Pathol Lab Med."},{"issue":"4","key":"20426_CR94","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/cas.13190","volume":"108","author":"S Takeuchi","year":"2017","unstructured":"Takeuchi S, Fukuda K, Yamada T, et al. Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. Cancer Sci. 2017;108(4):696\u2013703. https:\/\/doi.org\/10.1111\/cas.13190.","journal-title":"Cancer Sci."},{"issue":"3","key":"20426_CR95","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3892\/or.2013.2225","volume":"29","author":"E Yamaki","year":"2013","unstructured":"Yamaki E, Yajima T, Kosaka T, et al. Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype. Oncol Rep. 2013;29(3):932\u201340. https:\/\/doi.org\/10.3892\/or.2013.2225.","journal-title":"Oncol Rep."},{"issue":"20","key":"20426_CR96","doi-asserted-by":"publisher","first-page":"153303382110381","DOI":"10.1177\/15330338211038142","volume":"9","author":"X Wang","year":"2021","unstructured":"Wang X, Wang X, Carvalho V, Wang Q, Li T, Wang J, Chen Y, Ni C, Liu S, Zhang J. Prognostic value of podoplanin in various tumors. Tech Cancer Res Treat. 2021;9(20):15330338211038142.","journal-title":"Tech Cancer Res Treat."},{"issue":"4","key":"20426_CR97","doi-asserted-by":"publisher","first-page":"101600","DOI":"10.1016\/j.esmoop.2023.101600","volume":"8","author":"MV Dietz","year":"2023","unstructured":"Dietz MV, van Kooten JP, Paats MS, et al. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies. ESMO Open. 2023;8(4):101600. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101600.","journal-title":"ESMO Open."},{"issue":"3","key":"20426_CR98","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jtho.2021.09.012","volume":"17","author":"M Offin","year":"2022","unstructured":"Offin M, Yang SR, Egger J, et al. Molecular Characterization of Peritoneal Mesotheliomas. J Thorac Oncol. 2022;17(3):455\u201360. https:\/\/doi.org\/10.1016\/j.jtho.2021.09.012.","journal-title":"J Thorac Oncol."},{"issue":"1","key":"20426_CR99","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/modpathol.2015.121","volume":"29","author":"AD Singhi","year":"2016","unstructured":"Singhi AD, Krasinskas AM, Choudry HA, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29(1):14\u201324. https:\/\/doi.org\/10.1038\/modpathol.2015.121.","journal-title":"Mod Pathol."},{"issue":"10","key":"20426_CR100","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41417-022-00460-7","volume":"29","author":"R El Bezawy","year":"2022","unstructured":"El Bezawy R, Percio S, Ciniselli CM, et al. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. Cancer Gene Ther. 2022;29(10):1394\u2013404. https:\/\/doi.org\/10.1038\/s41417-022-00460-7.","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"20426_CR101","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-016-0387-6","volume":"10","author":"R El Bezawy","year":"2017","unstructured":"El Bezawy R, De Cesare M, Pennati M, et al. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10(1):19. https:\/\/doi.org\/10.1186\/s13045-016-0387-6.","journal-title":"J Hematol Oncol."},{"issue":"3","key":"20426_CR102","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3892\/ijo.2025.5729","volume":"66","author":"D Andreikos","year":"2025","unstructured":"Andreikos D, Spandidos DA, Georgakopoulou VE. Telomeres and telomerase in mesothelioma: pathophysiology, biomarkers and emerging therapeutic strategies. Int J Oncol. 2025;66(3):23. https:\/\/doi.org\/10.3892\/ijo.2025.5729.","journal-title":"Int J Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20426-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20426-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:33:51Z","timestamp":1794832431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20426-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":102,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["20426"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20426-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflict of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We registered our study protocol on the International Prospective Register of Systematic Reviews (PROSPERO) website with the registration number CRD420251164114.","order":2,"name":"Ethics","label":"Trial Registration","group":{"name":"EthicsHeading","label":"Ethics"}}]}}